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Abstract 
The human acidic fibroblast growth factor (hFGF-1) is a protein that plays an important role in 
many body processes such as angiogenesis and tissue repair. As such, it has great potential for 
therapeutic application. However, hFGF-1 is relatively unstable in the body with a significant 
fraction being denatured at body temperature and pH. It contains a group of positively charged 
amino acids in close proximity that create an electrostatic strain on the molecule and can lead to 
denaturation and increased susceptibility to enzymatic digestion. Upon its release from the cell, 
hFGF-1 binds to the glycosaminoglycan heparin in the extracellular matrix. Heparin stabilizes 
hFGF-1 by binding to this group of positively charged amino acids, known as the heparin 
binding pocket. Heparin also mediates the binding of hFGF-1 to cell surface FGF Receptors 
(FGFRs). When activated by hFGF-1, these receptors propagate a signal downstream to initiate 
various pathways inside the cell. This study examines a mutation of hFGF-1 in which two 
negative charges are introduced into the heparin binding pocket. The introduction of these 
charges decreased the binding affinity of hFGF-1 for heparin by about 3-fold. This mutation also 
showed similar bioactivity compared to wild type hFGF-1 (wt-hFGF-1) both in the presence and 
absence of heparin. Overall, these results suggest that heparin binding affinity is not positively 
correlated with mitogenic activity. Additionally, it was shown that heparin binding is not 
necessary for activation of the tyrosine kinase cell surface receptor.   
Introduction 
The fibroblast growth factor family (FGFs) are a group of signaling molecules with a vast array 
of biological functions [1, 2]. They exhibit their effects by binding to various isoforms of 4 cell 
surface receptors or FGFRs [3, 4]. hFGF-1 can bind to and activate all FGFR isoforms, and as 
such it is a good choice for clinical applications [5]. One such application is wound healing. 
Wound healing is generally divided into four stages: hemostasis, inflammation, proliferation, and 
remodeling [6]. During the third stage, proliferation, fibroblasts activated by FGFs proliferate 
epithelial cells and plug the wound with collagen [6]. This process begins several days to weeks 
after the injury [6]. This leaves the wound covered with only a blood clot before that time and 
relatively open to the environment. Because of this, during the first two phases of wound healing, 
the body is prone to infection. A serum containing hFGF-1 could be used to speed recovery from 
surgical incisions or other wounds, thereby lowering risk of infection [7]. It could also be used to 
treat slow healing chronic wounds in diabetes patients [7].  
In the body, hFGF–1 binds to heparin sulfate, a glycosaminoglycan present in the extracellular 
matrix that serves to stabilize hFGF-1 during its binding to an FGFR [3]. Heparin binds to hFGF-
1 via the heparin binding pocket, three surface loops that contain many positively charged amino 
acids near the c-terminal of the protein [8, 9]. Crystal structures of FGFR and hFGF-1 reveal that 
dimers formed both by receptors and growth factors seem to be mediated by heparin [10]. It is 
generally thought that heparin is necessary for FGFR activation [11].  
Thrombin is an enzyme that is present at a wound site and can cleave hFGF-1 at position R136 
[12]. A previous mutation studied by the Kumar lab of arginine at position 136 to glutamate 
showed a slight decrease in heparin binding affinity and a dramatic increase in stability and cell 
proliferation activity when compared to the wild type [13]. This study investigated whether the 
introduction of another negative charge, glutamate at position 135, in conjunction with an R136E 
mutation could further improve stability and cell proliferation activity. When two negative 
charges were introduced into the heparin binding pocket, the bioactivity was similar when 
compared to wild type both in the presence and absence of heparin. Additionally, the heparin 
binding affinity of the mutant was roughly 3 times lower than the wild type. Further study of 
mutations of proline at position 135 revealed that the single mutation of proline to glutamate at 
position 135 resulted in an increase in heparin binding affinity as compared to the wild type [13]. 
This suggests that the R136E mutation played a large role in the decreased heparin binding 
affinity of P135E/R136E [13]. Overall, these results show that the addition of the mutation 
P135E to the R136E mutation did not confer additional stability or bioactivity to the protein. 
However, an interesting finding was that mitogenic activity was not positively correlated with 
heparin binding affinity. Additionally, it was shown that heparin is helpful for providing stability 
during hFGF-1-FGFR binding, but it is not strictly necessary for activation of an FGFR by 
hFGF-1.  
Results and Discussion 
Structural changes  
hFGF-1 contains eight tyrosine residues and one tryptophan residue [14]. These aromatic amino 
acids can be used to identify the denatured state of the protein via intrinsic fluorescence. The 
tyrosine residues have a characteristic maximum fluorescence intensity at an emission 
wavelength of 308nm, while for tryptophan the maximum occurs at 350nm. hFGF-1 in its native 
state has a high intensity peak at 308nm and no peak at 350nm due to the quenching effect of the 
amino groups on the side chains which surround the tryptophan residue [15]. Its denatured state 
is determined by the presence of a large peak at 350nm due to the tryptophan residue shifting 
away from the quenching groups. Relative intrinsic fluorescence experiments were conducted to 
determine if the mutant appeared to be properly folded. The ratio of fluorescence values for 
308nm/350nm was lower in the mutant than in wt-hFGF-1 both in the presence and absence of 
heparin (Figure 1). Without heparin, the double mutant had a ratio of 1.76 while for wt-hFGF-1 
it was 7.20. With heparin, the double mutant had a ratio of 1.63 while for wt-hFGF-1, the ratio 
was 7.43. Although the ratio of 308/350nm was higher in the double mutant, than wt-hFGF-1, 
the characteristic fluorescence spectrum of the folded protein of a high peak at 308 and a drop 
thereafter is maintained. The increase in the ratio results from a broader shoulder in the double 
mutation around the wavelengths 320-380 nm. It is known that the indole side chain in W121 is 
quenched by the amino groups in the proline and lysine residues positioned nearby [15]. 
Additionally, W121 is positioned 3.5 Angstroms away from the pyrrole side chain of proline in 
native hFGF-1 [15]. Therefore, with the substitution of glutamate at position 135, it is plausible 
that the indole group is shifted away from the other quenching groups, creating this shoulder.  
Far UV Circular Dichroism (CD) is used to examine the secondary structure of proteins. The 
difference in the absorption of right and left circularly polarized light by the sample is used to 
calculate a value of molar ellipticity at various wavelengths. This can reveal patterns 
characteristic of alpha helices and beta sheets [16]. The CD data for the double mutant overlays 
well with wt-hFGF-1 (Figure 2). Both show the characteristic shape of a beta trefoil fold; a 
negative peak at 207nm and a positive peak at around 230nm. This indicates that the secondary 
structure is not significantly perturbed as a result of the mutation.  
8-Anilinonaphthalene-1-sulfonic acid (ANS) is a fluorescent molecular probe used to test for the 
presence of hydrophobic residues on the surface of proteins [17]. An increase in the fluorescence 
of ANS is indicative of a higher presence of hydrophobic residues that are solvent accessible 
[17]. ANS was added in increments of 20 µM to a sample of protein and fluorescence 
measurements were taken at 500 nm from 0 µM ANS to 400 µM ANS. The fluorescence 
measured for P135E/R136E in the presence and absence of heparin did not significantly differ 
from wt-hFGF-1 (Figure 3). This indicates that the tertiary structure is not significantly perturbed 
due to the introduction of two negative charges in the heparin binding pocket. This result 
corroborates with the intrinsic fluorescence and the CD spectra for this mutation.  
Nuclear magnetic resonance is a technique used to determine changes in the backbone 
arrangement of a protein. Its utility lies in its ability to give information about changes to specific 
residues [18]. Cells are grown in media with N15, a radioactive isotope of nitrogen. Protein is 
then extracted using established laboratory techniques. The protein samples are exposed briefly 
to a magnetic field which aligns all of the H nuclei. Then, the magnetic field is removed and 
nuclei are allowed to precess for a time, 𝑡1. During this time, the chemical shift of the H nucleus 
is labeled. Each proton attached to a heteronucleus (N15) produces a distinct peak in the 
spectrum. Then, magnetization is transferred to the second nucleus (N15), and the chemical shift 
of these nuclei is measured and labeled. Collectively, these can be combined to show the shift of 
each N15-H pair in each amino acid. If the spectra from two different samples are overlaid, the 
residues experiencing a change in conformation will experience a greater chemical shift and 
therefore will not overlap. The spectra for wt-hFGF-1 and P135E/R136E were overlaid (Figure 
4). G134 is the most perturbed amino acid in the heparin binding pocket and T83, G85, and G89 
are the most perturbed outside the heparin binding pocket. The proximity of these amino acids 
suggests that that the structural changes due to the mutation are just local. This corroborates well 
with the other structural experiments.    
Stability 
The stability of the mutant under thermal stress was measured in the presence and absence of 
heparin. The mutant was heated from 25℃ to 75℃ in 5 degree increments while measuring the 
fluorescence at 308 and 350nm to detect unfolding of the protein. The Tm (temperature at which 
50% of the protein in the sample is unfolded) for the mutant without heparin was 53℃, while for 
wt-hFGF-1 the Tm was 48.5 ℃ [15]. In the presence of heparin, the Tm for the double mutant 
was 57.7 ℃ while for wt-hFGF-1, the Tm is much higher, 69.0 ℃ [15]. The ∆Tm value for 
P135E/R136E is 4.7 ℃, while the ∆Tm for wt-hFGF-1 is 20.5 ℃[15]. Comparing the ∆Tm 
values illustrates that the mutant is not as stabilized by heparin as the wild type. This is likely 
due to the lower binding affinity of the mutant for heparin. Additionally, this mutation is slightly 
more thermally stable than wt-hFGF1 in the absence of heparin.  
Urea is a denaturing agent that can disrupt intramolecular hydrogen bonds and lead to 
denaturation of a protein [19]. Urea was titrated in to the protein samples from 0M to 6M and the 
fluorescence values at 308 and 350 nm were monitored to determine when the protein was 
unfolded (Figure 5). The mutant alone showed a 𝐶𝑚 (the concentration at which half of the 
protein is denatured) of 1.76 M. This is close to wt-hFGF1, which has a 𝐶𝑚 of 1.81 M. For the 
mutant, the 𝐶𝑚 in the presence of heparin was 2.27 M while for wt-hFGF1, the 𝐶𝑚 is 4.18. The 
∆𝐶𝑚 for the mutant and wild type are 0.5 M and 1.91 respectively. The stability of the mutant is 
similar to wt-hFGF-1 in the absence of heparin. In the presence of heparin, the mutant is not 
stabilized to the same degree as wt-hFGF-1 and is much more susceptible to denaturation by 
urea. This is again likely due to the fact that the mutant has a lower binding affinity to heparin 
than the wild type does. 
Heparin binding affinity 
Isothermal titration calorimetry (ITC) is used to measure the thermodynamic properties of the 
interaction between a protein and its ligand [20]. ITC was used to detect heat changes that 
occurred when heparin was injected into both a sample of hFGF-1 and P135E/R136E (Figures 6 
and 7). This was done by measuring the power required to maintain a temperature difference of 
zero between the sample cell containing protein and the reference cell containing buffer, both 
contained in an insulated, adiabatic system. The dissociation constant (𝐾𝑑) and the change in 
enthalpy (∆H) can also be measured using ITC.  
The dissociation constant (𝐾𝑑) of the mutant for heparin was increased as compared to the wild 
type: 𝐾𝑑= 4.6µM and 𝐾𝑑= 1.7µM respectively. Therefore, the heparin binding affinity was 
decreased for the mutant. In examining other mutations, it was found that substituting just one 
negative charge at position 135 (P135E) actually increased heparin binding affinity (𝐾𝑑 =      
0.58µM) [15]. Therefore, the mutation at position 136 likely has a large role in the decrease in 
heparin binding affinity of P135E/R136E [15]. The change in enthalpy was also measured. The 
change in enthalpy for the mutant was ∆H= -0.85 kcal/mol [15]. The magnitude of this change 
was smaller than the wild type (∆H= -2.14 kcal/mol) [15]. This indicates that there is not as 
much contact between the mutant and heparin as compared to the heparin-wt-hFGF-1 interaction 
[15].  
Bioactivity 
To measure cell proliferation, NIH3T3 (human fibroblast) cells treated with heparinase (to remove 
the heparin from the cell surface) were grown in a culture with the hFGF-1 mutant and wild type 
in the presence and absence of heparin (Figures 8 and 9). Cell number was measured after 24 
hours. The double mutant showed a similar bioactivity to wt-hFGF1 both in the presence and 
absence of heparin. Without heparin, the bioactivity of the mutant is slightly higher at higher 
concentrations of protein (10 and 50 ng/mL) than wt-hFGF-1. Upon the addition of heparin, the 
bioactivity of the mutant and the wild type are the same.  
Conclusions 
Overall, this study shows that while heparin increases the bioactivity of both wt-hFGF-1 and 
P135E/R136E, a decrease in heparin binding affinity did not negatively affect cell proliferation 
activity of the mutant. Additionally, it can be said that heparin is not strictly required for hFGF-1 
to active a cell surface receptor. The addition of a negative charge at position 135 to the R136E 
mutation did not confer additional stability or cell proliferation activity to hFGF-1. These results 
can direct further study of this protein with the goal of increasing stability and bioactivity of the 
protein for applications in wound healing.   
Materials and Methods 
Materials 
Primers were designed using Agilent primer design software, IDT DNA Inc, USA. Plasmid 
isolation was accomplished using kits from Qiagen USA. Site directed mutagenesis kits were 
purchased from Agilent. DH5a and BL-21 competent cells (Escherichia coli) were from Novagen 
Inc, USA. Lysogeny Broth (LB) was from EMD Milipore, USA. Heparin sephrose for the 
purification column was from GE Healthcare. All buffer components: (Na2HPO4, NaH2PO4,
NaCl, (NH4)SO4) were obtained from VWR Scientific Inc, USA. Low molecular weight heparin 
sodium salt used in experiments (molecular weight ~3kDa) was from Sigma and MP Biomedicals 
LLC.  NIH3T3 cells were from American Type Culture Collection. DMEM media, fetal bovine 
serum, and penicillin streptomycin used for bioactivity experiments were all from Thermo Fisher 
Scientific.  
Site directed mutagenesis and bacterial transformation 
pET20b bacterial expression vector was the template for site directed mutagenesis. Instructions 
for the QuikChange II XL kit were followed for SDM. The heat shock method was used to 
transform the plasmid into the DH5a competent cells, and the sequence was verified by UAMS. 
Overexpression of the mutant was then carried out using BL-21 competent cells. The cells were 
incubated overnight in LB media at 37℃. IPTG was added after an optical density (measured by 
Hitachi F-2500 spectrofluorometer) of 0.4-0.6 was reached. After overexpression, cells were lysed 
using sonication, and protein was separated by centrifugation for 1 hour at 19,000 rpm. No post 
translational modifications are known to occur in hFGF-1 [15]. Purification was carried out using 
a heparin sephrose resin column. Buffers with 10mM phosphate (Na2HPO4, NaH2PO4) and 25mM 
ammonium sulfate ((NH4)SO4) and pH of 7.2 with increasing NaCl concentrations were loaded 
into the column to elute the protein. wt-hFGF-1 eluted at 1500mM NaCl and the mutant eluted at 
800mM NaCl. The presence of protein was determined by SDS-PAGE analysis with a standard 
protein marker. Concentrations were determined using the Bradford assay with a Hitachi F-2500 
Fluorimeter. All protein samples were prepared using a 1:10 mole ratio of protein to heparin as 
this was found to achieve maximum cell proliferation activity.  
Structural Experiments 
Fluorescence and ANS experiments were performed on a Hitachi F-2500 fluorimeter at 25℃ with 
a slit width set to 2.5 nm. For fluorescence experiments, a quartz cuvette with path length of 1 cm 
was used with protein concentration of 1 mg/mL. An excitation wavelength of 280nm and emission 
wavelength range of 300-450nm were used. For the ANS assay, 1µL of 20mM stock ANS was 
added to the sample before each measurement to increase the concentration of ANS by 20µM 
increments. With each addition, the fluorescence value was measured at 500 nm.  
Far-UV CD was performed on a Jasco 1500 spectroploarimeter. A protein concentration of 
0.5mg/mL was used at 25℃. A sandwich cuvette used with path length 0.1 cm.  
For 2-D NMR a Bruker 500MHx NMR was used with a cryoprobe. A protein concentration of 
5mg/mL in 10mM PB (Na2HPO4, NaH2PO4), 100mM NaCl, 25mM (NH4)SO4), and a pH of 7.2 
at 25℃ was used. Data was analyzed using Sparky 3.114 software. Chemical shift was calculated 
using the formula √[(2ΔδNH)2 + (ΔδN)2]. 
 
 
Stability Experiments 
Thermal and chemical denaturation experiments were performed using a Jasco-1500 
spetropolarimeter, with a protein concentrations of 0.5mg/mL in 10mM PB 
(Na2HPO4, NaH2PO4), 100mM NaCl, 25mM (NH4)SO4), at a pH of 7.2. For thermal denaturation, 
the fraction unfolded was calculated using (Fx − F20)/(F80 − F20) where F is the fluorescence 
value at 308nm divided by the fluorescence value at 350nm and F20 and F80 are the fluorescence 
fractions at 20℃ and 80℃ respectively.  For urea denaturation, urea was steadily added to increase 
the urea concentration from 0M to 6M and at each addition, the fluorescence value at 308nm and 
350nm was recorded. The ratio of 308nm to 350nm was recorded and the fraction unfolded was 
calculated using (Fx − F0)/(F0 − F6). F is the fluorescence value at 308nm divided by the 
fluorescence value at 350nm and F0 and F6 are the fluorescence fractions at 0M urea and 6M urea 
respectively.   
Heparin Binding Affinity 
Heparin binding affinity was determined using ITC-200, Malvern Inc. Changes in heat were 
determined by titrating heparin into the reaction vessel containing the protein sample. Protein 
samples of 0.85mg/mL were made using 100mM NaCl and 25mM (NH4)SO4 at a pH of 7.2. The 
samples were degassed prior to titration. 30 titrations were performed at 25℃ and 1000 rpm stir 
speed. Corrections were applied to adjust for the heats of dilution.  
Cell Proliferation 
For cell proliferation experiments, NIH3T3 fibroblast cells from ATCC were cultured in DMEM 
with 10% FBS, 1% penicillin/streptomycin. When 80%-90% confluency was reached, the cells 
were incubated overnight in serum-free media at 37℃ with 5% carbon dioxide. Heparin on the cell 
surface was removed by adding heparinase (6 units to 10,000 cells). After washing cells with PBS, 
they were returned to DMEM. Heparin was then added in a 1:10 protein to heparin ratio. Cells 
were divided into wells with 10,000 cells per well. Protein was added to different cells at 
concentrations of 0, 0.4, 2, 10, and 50 ng/mL and then incubated for one day (24 hours). Then, the 
CellTiter-Glo (Promega, Madison, WI) cell proliferation assay was used to determine the quantity 
of NIH3T3 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend to Figures 
All experiments were conducted using a ratio of 1:10 protein to heparin. Protein samples were 
prepared in 10mM PB (Na2HPO4, NaH2PO4), 100mM NaCl, 25mM (NH4)SO4, at a pH of 7.2. 
All experiments with the exception of thermal denaturation and bioactivity were performed at 
25℃. Bioactivity experiments were performed at 37℃ and thermal denaturation experiments 
were performed in the range of 25℃-75℃. 
Figure 1:  A protein concentration of 1mg/mL was used. Relative fluorescence is shown on the 
y-axis at wavelengths from 300-450nm (shown on the x-axis).  
Figure 2: A protein concentration of 0.5mg/mL was used. Molar ellipticity is shown on the y-
axis at various wavelengths (shown on the x-axis).  
Figure 3: A protein concentration of 0.25mg/mL was used. Fluorescence at 500nm is shown on 
the y-axis and concentration of ANS is shown on the x-axis.  
Figure 4: A protein concentration of at least 5mg/mL was used. Chemical shift for hydrogen is 
shown on the x-axis and chemical shift for nitrogen is shown on the y-axis. The mutant is labeled 
red and the wild type is labeled blue.  
Figure 5: Protein samples were prepared with a protein concentration of 0.5mg/mL. Urea was 
titrated in from 0M to 6M urea and the fluorescence values at 308nm and 350nm were recorded 
to determine when the protein unfolded. The fraction of protein unfolded is shown on the y-axis. 
Figure 6 and 7: A protein concentration of 0.85mg/mL was used. The power requirement for the 
sample and reference cell to remain at the same temperature is shown in the upper portion of the 
graph. The energy change when heparin was added is shown in the bottom portion. The 𝐾𝑑 
(dissociation constant) is also displayed on the bottom portion of the graph.  
Figures 8 and 9: Protein concentrations are indicated by the different colored bars (refer to the 
legend at bottom of the graph) and the cell number is displayed on the y-axis. The proteins 
involved in this thesis are circled.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Intrinsic Fluorescence.  
 
Figure 2. Far UV Circular Dichroism. 
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Figure 3. ANS Binding.  
 
Figure 4. NMR Spectra.  
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Figure 5. Urea Denaturation. 
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Figures 6 and 7. ITC data for wt-hFGF-1. Reproduced from Julie Davis et al, Probing the Role of Proline 
135 on the Structure, Stability and Cell Proliferation Activity of Human Acidic Fibroblast Growth Factor. 
Archives of Biochemistry and Biophysics, 2018, volume 654, pages 115-125.   
 
 
 
 
Figure 8. Bioactivity data (without heparin). Reproduced from Julie Davis et al, Probing the Role of 
Proline 135 on the Structure, Stability and Cell Proliferation Activity of Human Acidic Fibroblast Growth 
Factor. Archives of Biochemistry and Biophysics, 2018, volume 654, pages 115-125.   
 
 
Figure 9. Bioactivity data (with heparin). Reproduced from Julie Davis et al, Probing the Role of Proline 
135 on the Structure, Stability and Cell Proliferation Activity of Human Acidic Fibroblast Growth Factor. 
Archives of Biochemistry and Biophysics, 2018, volume 654, pages 115-125.   
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